Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients

详细信息    查看全文

• 作者：Luisa Costa (1) (2)
  Francesco Caso (2)
  Mariangela Atteno (1)
  Antonio Del Puente (1)
  Md Abud Darda (3)
  Paolo Caso (4)
  Augusta Ortolan (2)
  Ugo Fiocco (2)
  Roberta Ramonda (2)
  Leonardo Punzi (2)
  Raffaele Scarpa (1)
  
• 关键词：Adalimumab ; Anti ; TNF ; α ; Etanercept ; Metabolic syndrome ; Methotrexate ; Psoriatic arthritis
• 刊名：Clinical Rheumatology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：33
• 期：6
• 页码：833-839
• 全文大小：
• 参考文献：1. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55-8 CrossRef
  2. Scarpa R, Altomare G, Marchesoni A, Balato N, Matucci Cerinic M, Lotti T, Olivieri I, Vena GA, Salvarani C, Valesini G, Giannetti A (2010) Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol 24:627-30 CrossRef
  3. Ritchlin CT (2008) From skin to bone: translational perspectives on psoriatic disease. J Rheumatol 35:1434-437
  4. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195-02 CrossRef
  5. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331-34 CrossRef
  6. Pereira RM, de Carvalho JF, Bonfá E (2009) Metabolic syndrome in rheumatological diseases. Autoimmun Rev 8:415-19 CrossRef
  7. Raychaudhuri SP (2012) Comorbidities of psoriatic arthritis—metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol 39:437-40 CrossRef
  8. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2012) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202325
  9. Zhu TY, Li EK, Tam LS (2012) Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012:714321 CrossRef
  10. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, Punzi L, Doria A (2011) Atherosclerosis in psoriatic arthritis. Autoimmun Rev 10:773-78 CrossRef
  11. Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14:343-48 CrossRef
  12. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM (2012) Increase in ventricular–arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 51:2215-223 CrossRef
  13. Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711-15 CrossRef
  14. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, Matucci-Cerinic M, Sitia S, Tomasoni L, Turiel M (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9:849-52 CrossRef
  15. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology 47:718-23 CrossRef
  16. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59:904-09 CrossRef
  17. Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, Bernardi D, Ramonda R, Plebani M, Punzi L (2009) Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol 27:79-3
  18. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415-428 CrossRef
  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-497 CrossRef
  20. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75:235-40 CrossRef
  21. Scrivo R, Vasile M, Bartosiewicz I, Valesini G (2011) Inflammation as “common soil-of the multifactorial diseases. Autoimmun Rev 10:369-74 CrossRef
  22. Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347-55 CrossRef
  23. Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346-57 CrossRef
  24. Sethi JK, Hotamisligil GS (1999) The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19-9 CrossRef
  25. Fonseca JE, Santos MJ, Canh?o H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538-42 CrossRef
  26. Mease PJ (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298-04 CrossRef
  27. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6:524-28 CrossRef
  28. Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A (2011) Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev 10:631-35 CrossRef
  29. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33:2440-446
  30. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K (2002) Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114:1004-007
  31. Stinco G, Piccirillo F, Patrone P (2007) Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 157:1273-274 CrossRef
  32. Castro KR, Aikawa NE, Saad CG, Moraes JC, Medeiros AC, Mota LM, Silva CA, Bonfá E, Carvalho JF (2011) Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol 2011:352686
  33. Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC (2006) Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care 29:1712-713 CrossRef
  34. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665-673 CrossRef
  35. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48-3 CrossRef
  36. Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62:965-69 CrossRef
  37. Gremese E, Ferraccioli G (2011) The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 10:582-89 CrossRef
  
• 作者单位：Luisa Costa (1) (2)
  Francesco Caso (2)
  Mariangela Atteno (1)
  Antonio Del Puente (1)
  Md Abud Darda (3)
  Paolo Caso (4)
  Augusta Ortolan (2)
  Ugo Fiocco (2)
  Roberta Ramonda (2)
  Leonardo Punzi (2)
  Raffaele Scarpa (1)
  
  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University Federico II, via S. Pansini 5, 80131, Naples, Italy
  2. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
  3. Department of Statistical Sciences, University of Padova, Padova, Italy
  4. Sapienza Università di Roma, Rome, Italy
  
• ISSN：1434-9949

文摘

Psoriatic arthritis (PsA) is a chronic inflammatory condition, characterized by an excess of metabolic disorders. Metabolic syndrome (MetS) is a cluster of classic cardiovascular risk factors, due to an imbalance between pro- and anti-inflammatory adipokines. Tumor necrosis factor (TNF)-α is a pro-inflammatory adipocytokine mainly produced by monocytes and macrophages with a central role in inflammatory responses, but it also induces adipocytes apoptosis, promotes insulin resistance, and stimulates lipolysis. The aim of this study was to evaluate the impact of therapy with etanercept (ETN), adalimumab (ADA), and methotrexate (MTX) on MetS components in a cohort of PsA patients with a follow-up period of 24?months. A retrospective study has been conducted in a cohort of PsA patients. On the basis of the inclusion criteria, we identified the first 70 consecutive patients, respectively, on ADA, ETN, and MTX, for a total of 210 patients achieving PsARC criteria during the observation period. As part of the routine clinical practice, assessment of metabolic parameters and of disease activity was recorded at baseline (T0), at 12?months (T1), and at 24?months (T2). The results show that when the specific components of the MetS were considered, taking also into account by regression analysis the effect of the confounding factors, the patients on etN and ADA show a significant improvement of the metabolic syndrome components (in detail, waist circumference, triglycerides, high-density lipoprotein cholesterol, and glucose) as compared to the MTX group. In conclusion, these data suggest that the biologic treatment in PsA can no longer be taken into consideration only for its positive effect on articular and cutaneous symptoms but also on the various aspects of this complex picture.